Boston, MA – June 3, 2026 – Moonlight Therapeutics, a pioneering biopharmaceutical company dedicated to transforming the treatment of severe allergies, today announced the commencement of the SURVEYOR Phase I clinical trial. This groundbreaking study marks the first-in-human evaluation of MOON101, an investigational immunotherapy designed to safely and effectively modulate the immune response in individuals suffering from peanut allergy. The initiation of SURVEYOR signifies a critical transition for MOON101, moving from promising preclinical research into rigorous human clinical evaluation, offering a beacon of hope for millions affected by this potentially life-threatening condition.
The SURVEYOR trial, an ascending-dose, open-label study, is set to enroll up to 40 participants across multiple clinical sites throughout the United States. Its primary objective is to meticulously assess the tolerability and safety profile of MOON101 in a diverse patient population, encompassing adults, adolescents, and children diagnosed with peanut allergy. This pioneering approach utilizes a novel delivery system, positioning MOON101 as a potentially convenient and minimally invasive treatment option.
Key Facts: A New Dawn for Peanut Allergy Management
At its core, the SURVEYOR trial represents a significant advancement in the quest for effective peanut allergy treatments. For decades, the primary approach to managing peanut allergy has been strict avoidance of the allergen, a challenging and often anxiety-inducing strategy for patients and their families. While epinephrine auto-injectors are crucial for managing acute allergic reactions, they do not address the underlying immune hypersensitivity. MOON101 aims to fundamentally alter this landscape by retraining the immune system to tolerate peanuts.
The investigational therapy, MOON101, is an allergen-specific immunotherapy delivered via a revolutionary microneedle skin stamp. This innovative device enables the precise and rapid delivery of microgram doses of peanut extract directly into the skin. The application process is designed to be swift, taking mere minutes, and holds the potential for at-home administration, thereby significantly reducing the burden on patients and caregivers. This focus on patient convenience is a cornerstone of Moonlight Therapeutics’ development strategy, aiming to make immunotherapy more accessible and manageable.
The trial is specifically targeting individuals with physician-confirmed peanut allergy, a critical criterion to ensure accurate diagnosis and appropriate participant selection. The age range for enrollment is broad, spanning from four to 55 years, reflecting the widespread impact of peanut allergy across different life stages. This inclusivity is vital for understanding the drug’s safety and efficacy across a spectrum of immune system responses and developmental stages.
Chronology: From Preclinical Promise to Clinical Reality
The journey of MOON101 to this first-in-human trial has been marked by diligent research and strategic development. The SURVEYOR study’s launch follows a thorough review process by the U.S. Food and Drug Administration (FDA), which granted Moonlight Therapeutics’ investigational new drug (IND) application. This approval signifies that the FDA has determined the proposed clinical trial to be reasonably safe to proceed.
Furthermore, the trial benefits from substantial prior support from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health. NIAID’s funding has been instrumental in advancing the preclinical understanding of MOON101 and has provided crucial early-stage validation for the therapeutic concept. This collaborative environment, involving regulatory bodies and governmental research institutions, underscores the scientific rigor and potential impact of MOON101.
The SURVEYOR trial will proceed in a phased manner within its Phase I design. Initially, adult participants will be enrolled and undergo treatment. Subsequently, adolescent and child participants will be incorporated into the study. This staggered approach allows for careful observation of dose escalation and potential side effects in different age groups, ensuring a systematic and safety-conscious progression. Participants will attend five scheduled visits over the course of the trial, during which escalating doses of MOON101 will be administered.
Supporting Data: The Science Behind MOON101
The innovative design of MOON101 is rooted in the principles of allergen-specific immunotherapy, a well-established but often cumbersome treatment modality. Traditional oral or sublingual immunotherapy requires daily administration of increasing doses of allergen, which can lead to significant side effects and adherence challenges. The microneedle stamp technology employed by MOON101 represents a significant leap forward in delivery systems.
Microneedle patches are designed to penetrate the outermost layers of the skin, the epidermis, and reach the dermis, which is rich in immune cells. This superficial delivery targets key components of the immune system, such as Langerhans cells and dendritic cells, which play a crucial role in initiating and regulating immune responses. By delivering the allergen directly to these antigen-presenting cells in a controlled manner, MOON101 aims to induce a state of immune tolerance.
The delivery of microgram doses is a critical aspect of the therapy. This precision dosing is intended to avoid triggering a systemic allergic reaction while still providing sufficient antigenic stimulus to modulate the immune system. The rapid administration, within minutes, further enhances the patient experience and reduces the time commitment associated with treatment.
The trial’s protocol is designed to meticulously track several key endpoints. These include:
- Treatment-Emergent Adverse Events (TEAEs): A comprehensive monitoring of any adverse reactions that arise during or after treatment, with particular attention to allergic symptoms, local skin reactions at the application site, and systemic side effects.
- Overall Tolerability: Assessing how well participants can tolerate the treatment regimen, including the comfort of the microneedle application and the absence of significant discomfort or distress.
- Immune Responses to the Therapy: This will involve a battery of immunological assays to measure changes in the participants’ immune system. This may include evaluating the production of specific antibodies (e.g., IgG4, which is often associated with tolerance), the activity of T-cells involved in immune regulation, and markers of basophil and mast cell activation. The goal is to demonstrate that MOON101 is successfully shifting the immune response away from a hypersensitive state towards one of tolerance.
The collaboration with leading academic food allergy centers across the US is a crucial element of the SURVEYOR trial’s execution. These partnerships ensure that the study adheres to the highest standards of scientific integrity, ethical conduct, and data quality. The expertise of these centers in managing food allergy patients and conducting early-phase clinical trials will provide robust safety oversight and ensure uniform trial conduct, maximizing the reliability of the collected data.
Official Responses: A Vision for Patient-Centric Care
Samir Patel, Co-Founder and CEO of Moonlight Therapeutics, expressed profound optimism regarding the commencement of the SURVEYOR trial. "This is an exciting milestone for Moonlight Therapeutics and for the millions of families impacted by peanut allergy," stated Patel. "Initiating SURVEYOR marks the transition of MOON101 from promising preclinical research into human studies. Our goal is to develop a patient-friendly therapy capable of safely modulating the immune response to peanuts and ultimately reducing the risk of severe allergic reactions."
Patel’s statement highlights the company’s dual focus: scientific innovation and patient well-being. The emphasis on a "patient-friendly therapy" underscores the potential of MOON101 to overcome the practical and psychological barriers associated with current allergy management strategies. The ultimate aim, as articulated by Patel, is not just symptom management but a fundamental alteration of the immune system’s response, leading to a tangible reduction in the risk of life-threatening anaphylaxis.
The collaboration with academic institutions is also a testament to the company’s commitment to rigorous scientific validation and transparency. By partnering with established experts in the field, Moonlight Therapeutics is building a strong foundation for the successful execution of the SURVEYOR trial and future development of MOON101.
Implications: Transforming the Future of Allergy Treatment
The successful development and approval of MOON101 could have profound implications for individuals with peanut allergy and the broader field of allergy immunotherapy.
For Patients and Families:
- Reduced Anxiety and Improved Quality of Life: The prospect of a treatment that can safely desensitize the immune system could significantly alleviate the constant anxiety surrounding accidental exposure to peanuts. This could lead to a substantial improvement in the quality of life for individuals with peanut allergy and their families, allowing for greater freedom and participation in social activities.
- Increased Treatment Accessibility: The potential for at-home administration, if validated in later-stage trials, would revolutionize access to immunotherapy. This would reduce the need for frequent clinic visits, saving time and resources for patients, particularly those in rural or underserved areas.
- Potential for Reduced Severity of Reactions: By retraining the immune system, MOON101 aims to not only reduce the frequency of allergic reactions but also to lessen their severity, potentially preventing life-threatening anaphylactic episodes.
For the Medical Community:
- A New Therapeutic Paradigm: MOON101 could establish a new paradigm for allergen-specific immunotherapy, moving away from traditional, often burdensome methods towards more convenient and patient-centric approaches.
- Broader Application of Microneedle Technology: The success of MOON101 could pave the way for the application of microneedle technology in the development of immunotherapies for other allergens, such as milk, egg, or pollen.
- Enhanced Understanding of Immune Tolerance: The detailed immunological data generated from the SURVEYOR trial and subsequent studies will contribute significantly to the scientific understanding of how immune tolerance is induced and maintained, potentially informing research into other immune-mediated diseases.
For the Pharmaceutical Industry:
- Innovation in Drug Delivery: The successful implementation of the microneedle stamp for immunotherapy could spur further innovation in drug delivery systems across various therapeutic areas.
- Market Opportunities: The significant unmet need for effective and convenient allergy treatments presents a substantial market opportunity for companies that can develop and commercialize novel therapies.
While the SURVEYOR trial is in its initial stages, the commencement of this first-in-human study represents a significant leap forward in the fight against peanut allergy. The innovative approach of MOON101, coupled with a strong scientific foundation and a patient-centric development strategy, positions Moonlight Therapeutics at the forefront of a new era in allergy treatment. The coming months and years will be crucial in determining whether MOON101 can fulfill its promise and offer a transformative solution for the millions worldwide affected by this pervasive and often dangerous allergy.
About the Author
